Akebia Therapeutics, Inc. (AKBA) is a publicly traded Healthcare sector company. As of May 21, 2026, AKBA trades at $1.01 with a market cap of $270.94M and a P/E ratio of -12.30. AKBA moved +12.28% today. Year to date, AKBA is -33.11%; over the trailing twelve months it is -65.41%. Its 52-week range spans $0.88 to $4.08. Analyst consensus is strong buy with an average price target of $4.67. Rallies surfaces AKBA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Akebia Therapeutics, Inc. (AKBA) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. AKBA moved +12.28% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $1.01 |
| Market Cap | $270.94M |
| P/E Ratio | -12.30 |
| EPS | $-0.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.08 |
| 52-Week Low | $0.88 |
| Volume | 302 |
| Avg Volume | 0 |
| Revenue (TTM) | $232.40M |
| Net Income | $-20.51M |
| Gross Margin | 81.01% |
3 analysts cover AKBA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.67.